What We Do

From production to patent: The CureVac way

All of our mRNA-based active ingredients for various fields of application originate from a common technology platform and are based on identical source materials. This enables CureVac to produce all mRNA using a universal process—even at a Good Manufacturing Practice (GMP) level of quality. CureVac is truly a one-stop shop for mRNA therapeutics, encompassing every step along the R&D journey, from discovery to production. Our high standards for discovery and production have led to high returns—we currently have over 700 granted patents, with almost 500 additional patent applications pending for approval.

mRNA production, inspired by programming

At CureVac, we describe our production philosophy as “biopharma meets IT.” Much like a programmer will write a code that carries instructions to a computer, during our R&D process, we use mRNA sequences to “write” a new “code” that will be translated by the body to the corresponding protein. This process means we have the possibility to use the same, standardized process to produce all of our mRNA therapeutics.

Where the science happens

CureVac has developed the entire, end-to-end manufacturing process itself and has extensive intellectual property covering its production techniques and technologies. We manufacture our mRNA therapeutics in our own GMP-compliant plants, which are 100% dedicated to producing high-quality mRNA molecules for biomedicine—including the world’s first. Our production plants are:

GMP certified
Our plants have been inspected by competent authorities and authorized for production of clinical trial material
Reproducible
One production facility can be used for mRNA products with different sequences and is a template for additional facilities
Standardized
Production process for all mRNA constructs is standardized across plants
Flexible
Quickly able to switch to production of new products
Scalable
Scale-up for industrial manufacturing possible

Our GMP-compliant facilities


Meet The RNA Printer® : our mobile production facility

No longer will mRNA therapeutic production be limited by large facility production. We are continuing to develop a portable mRNA “printing” facility – we call it The RNA Printer®. Producing ≥1g of product every two weeks, The RNA Printer® assists with a rapid response to outbreaks and can be stationed in hospitals to provide personalized medicine.